Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
Traws Pharma, a clinical stage biopharmaceutical company, has announced a corporate update call scheduled for August 15, 2024, at 8:00 AM ET. This call follows the release of their second quarter financial results. The company, which focuses on developing oral small molecules for respiratory viral diseases and cancer, will provide insights into their current operations and future plans.
Investors and interested parties can access the webcast through a provided link or join via phone using specific dial-in numbers for US and international callers. The financial results press release will be available on the company's website prior to the call, and a replay will be accessible afterwards in the Investor Relations section.
This corporate update presents an opportunity for stakeholders to gain valuable information about Traws Pharma's progress and financial standing, potentially impacting investment decisions related to the TRAW stock.
Traws Pharma, un'azienda biofarmaceutica in fase clinica, ha annunciato una chiamata di aggiornamento aziendale programmata per 15 agosto 2024, alle 8:00 AM ET. Questa chiamata segue la pubblicazione dei risultati finanziari del secondo trimestre. L'azienda, che si concentra sullo sviluppo di piccole molecole orali per malattie virali respiratorie e cancro, fornirà informazioni sulle sue operazioni attuali e sui piani futuri.
Investitori e parti interessate possono accedere alla trasmissione web tramite un link fornito oppure unirsi per telefono utilizzando numeri specifici per i chiamatori statunitensi e internazionali. Il comunicato stampa riguardante i risultati finanziari sarà disponibile sul sito web dell'azienda prima della chiamata e una replica sarà accessibile successivamente nella sezione Relazioni con gli Investitori.
Questo aggiornamento aziendale offre un'opportunità ai portatori di interesse per ottenere informazioni preziose sui progressi di Traws Pharma e la sua posizione finanziaria, potenzialmente influenzando le decisioni d'investimento relative al TRAW stock.
Traws Pharma, una empresa biofarmacéutica en etapa clínica, ha anunciado una llamada de actualización corporativa programada para 15 de agosto de 2024, a las 8:00 AM ET. Esta llamada sigue a la publicación de sus resultados financieros del segundo trimestre. La empresa, que se centra en el desarrollo de pequeñas moléculas orales para enfermedades virales respiratorias y cáncer, proporcionará información sobre sus operaciones actuales y planes futuros.
Los inversores y partes interesadas pueden acceder a la transmisión web a través de un enlace proporcionado o unirse por teléfono usando números específicos para los llamadores de EE.UU. e internacionales. El comunicado sobre los resultados financieros estará disponible en el sitio web de la empresa antes de la llamada, y una repetición estará accesible después en la sección de Relaciones con Inversores.
Esta actualización corporativa presenta una oportunidad para que los interesados obtengan información valiosa sobre el progreso de Traws Pharma y su situación financiera, potencialmente impactando las decisiones de inversión relacionadas con las acciones de TRAW.
Traws Pharma는 임상 단계에 있는 생명공학 제약 회사로, 2024년 8월 15일 오전 8:00 ET에 예정된 기업 업데이트 콜을 발표했습니다. 이 콜은 두 번째 분기 재무 결과 발표 이후에 진행됩니다. 호흡기 바이러스 질환 및 암을 위한 경구용 소분자 개발에 집중하는 이 회사는 현재 운영 및 미래 계획에 대한 통찰력을 제공할 것입니다.
투자자 및 이해 관계자는 제공된 링크를 통해 웹 캐스트에 액세스하거나 미국 및 국제 전화 참가자를 위한 특정 전화 번호를 사용하여 참여할 수 있습니다. 재무 결과 보도 자료는 콜 전에 회사 웹사이트에서 제공되며, 이후 투자자 관계 섹션에서 재생할 수 있습니다.
이 기업 업데이트는 이해 관계자가 Traws Pharma의 진행 상황 및 재무 상태에 대한 귀중한 정보를 얻을 수 있는 기회를 제공하여 TRAW 주식과 관련된 투자 결정을 잠재적으로 영향을 미칠 수 있습니다.
Traws Pharma, une entreprise biopharmaceutique en phase clinique, a annoncé un appel de mise à jour d'entreprise prévu pour le 15 août 2024 à 8h00 ET. Cet appel fait suite à la publication de leurs résultats financiers du deuxième trimestre. L'entreprise, qui se concentre sur le développement de petites molécules orales pour les maladies virales respiratoires et le cancer, fournira des informations sur ses opérations actuelles et ses plans futurs.
Les investisseurs et les parties intéressées peuvent accéder au webinaire via un lien fourni ou rejoindre par téléphone en utilisant des numéros spécifiques pour les appelants américains et internationaux. Le communiqué de presse concernant les résultats financiers sera disponible sur le site Web de l'entreprise avant l'appel, et une rediffusion sera accessible par la suite dans la section Relations Investisseurs.
Cette mise à jour d'entreprise offre une occasion aux parties prenantes d'obtenir des informations précieuses sur les progrès de Traws Pharma et sa situation financière, ce qui pourrait potentiellement influencer les décisions d'investissement liées aux actions TRAW.
Traws Pharma, ein biopharmazeutisches Unternehmen in der klinischen Phase, hat einen Unternehmens-Update-Call für 15. August 2024, um 8:00 Uhr ET angekündigt. Dieser Call folgt auf die Veröffentlichung ihrer finanziellen Ergebnisse für das zweite Quartal. Das Unternehmen, das sich auf die Entwicklung von oral vermittelten kleinen Molekülen gegen Atemwegsviruserkrankungen und Krebs konzentriert, wird Einblicke in seine aktuellen Aktivitäten und zukünftigen Pläne geben.
Investoren und Interessierte können über einen bereitgestellten Link auf das Webinar zugreifen oder sich telefonisch unter spezifischen Einwähl-Nummern für US-amerikanische und internationale Anrufer einwählen. Die Pressemitteilung zu den finanziellen Ergebnissen wird vor dem Anruf auf der Unternehmenswebsite verfügbar sein, und eine Wiederholung wird anschließend im Bereich Investor Relations zugänglich sein.
Dieses Unternehmensupdate bietet den Stakeholdern die Möglichkeit, wertvolle Informationen über den Fortschritt von Traws Pharma und die finanzielle Lage zu erhalten, was potenzielle Auswirkungen auf die Investitionsentscheidungen im Zusammenhang mit den TRAW-Aktien haben könnte.
- None.
- None.
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that following the release of its second quarter financial results, the Company intends to host a conference call and live webcast on Thursday, August 15, at 8:00 AM ET to provide a corporate update.
Conference Call and Webcast Information
Date: Thursday, August 15, 2024
Time: 8:00 AM ET
Webcast Link: Traws Pharma Corporate Update Call
Dial-in Numbers: (877) 407-0789 (United States), (201) 689-8562 (International)
Conference ID: 13748066
The press release with the financial results will be accessible prior to the conference call through “Press Releases” in the Investors & Media section of the company’s website. A replay of the call will also be available through “Corporate Events & Presentations” in the Investor Relations section of the company’s website.
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer. The viral respiratory disease program includes two potentially best in class oral small molecules in Phase 1 studies: tivoxavir marboxil, a novel oral antiviral drug candidate for influenza and avian flu, targeting the influenza cap-dependent endonuclease, and ratutrelvir, targeting Mpro (3CL protease).
In the cancer program, Traws is developing the novel, proprietary multi-kinase CDK4-plus inhibitor narazaciclib, with potential for refractory endometrial cancer and potentially other solid tumor cancers, and rigosertib, a PLK1 inhibitor, with potential for use in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC).
Traws Pharma is committed to delivering novel compounds for unmet medical needs using state-of-the-art drug development technology. With a focus on product safety and a commitment to patients in need or that are specifically vulnerable, we aim to build solutions for important medical challenges and alleviate the burden of viral infections and cancer.
Traws Pharma Contact:
Mark Guerin
Traws Pharma, Inc.
267-759-3680
www.trawspharma.com
Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
When is Traws Pharma (TRAW) hosting its corporate update call?
How can investors access Traws Pharma's (TRAW) corporate update call?
What will Traws Pharma (TRAW) discuss in its August 15, 2024 call?
Where can investors find Traws Pharma's (TRAW) financial results before the call?
